Interventional Oncology Market - Global Forecast to 2026 - Expansion in the Emerging Markets - ResearchAndMarkets.com
29 Nov 2022
Radiation Therapy
DUBLIN--(BUSINESS WIRE)--The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
'Interventional Oncology Global Market - Forecast to 2026'
The Interventional Oncology Global Market is Expected to Grow at a High Single Digit CAGR from 2019 to 2026 to Reach $2,119.4 Million by 2026
The interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures.
Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth.
The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029.
Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022.
Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029.
Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications.
The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029.
Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029.
The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029.
North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit growth rate. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market.
The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares.
Factors Influencing Market
Drivers and Opportunities
Increasing Incidence of Cancer Cases
Growing Adoption of Minimally Invasive Procedures
Increasing Geriatric Population
Technological Advancements in the Field of Interventional Oncology
Expansion in the Emerging Markets
Restraints and Threats
Side Effects and Risks Associated With the Use
Lack of Awareness
Lack of Trained Professionals
Availability of Alternative Treatments
Stringent Regulatory Guidelines
Some of the major players in the interventional oncology market include
Cdh Investments (Cdh Gentech Ltd), (Sirtex Ltd.)
Guerbet
Medtronic, plc
Interventional Oncology Global Market Share Analysis
Io Ablation Global Market Share Analysis
Io Embolization Global Market Share Analysis
Radiofrequency Ablation Global Market Share Analysis
Io Microwave Ablation Global Market Share Analysis
Io Tare Global Market Share Analysis
Io Deb-Tace Global Market Share Analysis
Io Tae Global Market Share Analysis
Interventional Oncology Global Market, Based on Product
Ablation
Radiofrequency Ablation
Microwave Ablation
Cryoablation
Other Ablation
Embolization
Io Trans-Arterial Radio-Embolization(Tare)/ Selective Internal Radiation Therapy (Sirt)
Io Transarterial Chemo-Embolization (Tace)
Io Drug-Eluting Beads Transarterial Chemo-Embolization (Deb-Tace)
Io Bland Embolization/ Transarterial Embolization (Tae)
Interventional Oncology Global Market, Based on Application
Other Applications
Regulatory Affairs
International Organization for Standardization
Iso 9001: 2015 Quality Management System
Iso:13485 Medical Devices
Iso 10993 Biological Evaluation of Medical Devices
Iso 14971 Risk Management of Medical Devices
Iso 12807:2018 Safe Transport of Radioactive Materials- Leakage Testing on Packages
Iec 60601-1 Medical Electrical Equipment Standard
Iec 60601-1-2 Electromagnetic Compatibility (Emc) for Medical Devices
U.S.
Canada
Europe
Japan
China
India
Companies Mentioned
Accutarget Medipharma (Shanghai) Co. Ltd
Bvm Medical Limited
Changi Jianyuan Technology Development
Diros Technology Inc.
Guerbet
Haifu Medical
Ice Cure Medical
Medtronic, plc
Siemens Healthineers (Varian)
Sirtex Medical Limited/Cdh
Symple Surgery
For more information about this report visit https://www.researchandmarkets.com/r/b0hcna
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.